Thyroid cancer in the age of COVID-19.

Field	Value	Language
dc.contributor.author	Tsang, Venessa Hm	en
dc.contributor.author	Gild, Matti	en
dc.contributor.author	Glover, Anthony	en
dc.contributor.author	Clifton-Bligh, Roderick	en
dc.contributor.author	Robinson, Bruce G	en
dc.date.accessioned	2020-09-14
dc.date.available	2020-09-14
dc.date.issued	2020	en
dc.identifier.uri	https://hdl.handle.net/2123/23351
dc.description.abstract	COVID-19 has modified the way we practice medicine. For thyroid cancer, there have been several significant impacts. Firstly, diagnosis has been delayed due to social isolation, reduced access to investigations and staff redeployment. Secondly, treatment planning has needed to take into account the risk to patients and/or staff of nosocomial transmission of the virus. Finally, there are some specific concerns with respect to interactions between the virus, its treatments and cancer. This mini review aims to address each of these impacts and to provide some guidance and confidence to our patients and colleagues during this challenging time.	en
dc.language.iso	en	en
dc.rights	Other
dc.subject	COVID-19	en
dc.subject	Coronavirus	en
dc.title	Thyroid cancer in the age of COVID-19.	en
dc.type	Article	en
dc.identifier.doi	10.1530/erc-20-0279
usyd.faculty	Faculty of Medicine and Health, Sydney Medical School	en

Associated file/s

There are no files associated with this item.